Navigation Links
SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
Date:2/2/2009

BOTHELL, Wash., Feb. 2 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced that the board of directors has appointed Bruce S. Morra, Ph.D., M.B.A., to serve as president and chief executive officer. Dr. Morra has served as a member of the SCOLR Pharma board of directors since August 2007.

Michael N. Taglich, Chairman of SCOLR Pharma's board of directors, said, "We are very pleased that Dr. Morra has agreed to become SCOLR Pharma's CEO. Since Dr. Morra's appointment to the board, he has been an able and trusted advisor. Given our longstanding belief that SCOLR's success will stem from maximizing opportunities for our proprietary CDT(R) technology in the pharmaceutical and over-the-counter arena, Dr. Morra's level of experience earned as an executive at numerous specialty pharmaceutical and healthcare companies coupled with his strategic alliance and business development expertise, makes him the right executive to assume leadership of our Company."

Dr. Morra has extensive experience in the pharmaceutical, medical device, biotechnology and polymers industries. Since 1998, Dr. Morra has been a Board Member and consultant for various public and private life science companies. He previously served as the President of West Pharmaceutical Services Drug Delivery and Contract Clinical Research businesses. Prior to this, Dr. Morra held several senior executive management positions including as Chief Business Officer of Progenitor Cell Therapy, as President, COO and CFO of Biopore Corporation and Polygenetics, Inc., as President, COO and Founder of Flamel Technologies, Inc's U.S. subsidiary, and as President of ISP Filters, a subsidiary of GAF Corporation. He received his B.S.E in Chemical Engineering from Princeton, a Ph.D. in Polymer Science and Engineering and an M.B.A. from the University of Massachusetts at Amherst.

Commenting on his appointment, Dr. Morra, said, "The b
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
2. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
3. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
4. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
5. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
6. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
7. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
8. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
9. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
10. China Biopharma, Inc. Issues Corporate Information Update
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... a radiology department and distributed through the medical director,s office, ... to significantly reduce the number of unnecessary cervical spine radiographs ... in the July issue of the Journal of the ... At the University of Rochester Medical Center in Rochester, NY, ...
... people worldwide do not have adequate access to surgical ... School of Public Health (HSPH). The researchers also found ... access to operating theatres (surgery sites) than those living ... settings often lack essential equipment. , A substantial ...
... When it comes to executing items on tomorrow,s to-do list, ... say psychologists at Washington University in St. Louis. People ... their intentions much better than people who try to execute ... that sleep enhances our ability to remember to do something ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... disease patients who received fetal cell transplants in the ... can prevent the troublesome side effect. The findings ... said. "These findings lend much optimism to new ...
... There are 8.3 million children who are 5 years ... to formal education, can media intervention make a positive ... Sesame Workshop, which produces Kilimani Sesame, the Tanzanian version ... Hopkins Bloomberg School of Public Health in full collaboration ...
... ... , ... (PRWEB) June 30, 2010 -- Greenway Medical Technologies, Inc., provider of the integrated, single-database ... awarded a patent for its innovative template builder module used to create custom clinical ...
Cached Medicine News:Health News:Top down approach helps academic medical center reduce unnecessary emergency department X-rays 2Health News:More than 2 billion people worldwide lack access to surgical services 2Health News:Memory links to 40 winks 2Health News:Memory links to 40 winks 3Health News:Memory links to 40 winks 4Health News: Parkinson's Transplant Mystery Solved, Researchers Say 2Health News: Parkinson's Transplant Mystery Solved, Researchers Say 3Health News:Kilimani Sesame has positive impact on children in Tanzania: Johns Hopkins University study 2Health News:Greenway Awarded U.S. Patent For EHR Functionality and Workflow 2Health News:Greenway Awarded U.S. Patent For EHR Functionality and Workflow 3Health News:Greenway Awarded U.S. Patent For EHR Functionality and Workflow 4
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
This set offers the full range of Keeler magnifiers and telescopes....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
Medicine Products: